Krishnadasan B, Naidu B, Rosengart M, Farr A L, Barnes A, Verrier E D, Mulligan M S
Division of Cardiothoracic Surgery, University of Washington, Seattle 98195, USA.
J Thorac Cardiovasc Surg. 2002 Apr;123(4):756-67. doi: 10.1067/mtc.2002.120351.
Calcineurin inhibitors reduce experimental reperfusion injury in the liver, brain, heart, kidney, and small bowel. These studies were undertaken to determine whether these agents are similarly protective against lung ischemia-reperfusion injury.
Left lungs of male rats were rendered ischemic for 90 minutes and reperfused for as long as 4 hours. Treated animals received cyclosporine A (INN: ciclosporin; 1 or 5 mg/kg) or tacrolimus (0.2 mg/kg) 6 hours before ischemia, at reperfusion, or 2 hours after reperfusion. Injury was quantitated in terms of tissue polymorphonuclear leukocyte accumulation (myeloperoxidase content), vascular permeability (iodine 125-labeled bovine serum albumin extravasation), and bronchoalveolar lavage leukocyte content. Separate tissue samples were processed for nuclear protein and cytokine messenger RNA.
Treatment with cyclosporine (5 mg/kg) or tacrolimus (0.2 mg/kg) 6 hours before reperfusion reduced lung vascular permeability by 54% and 56% relative to control animals (P <.03). The protective effects of cyclosporine and tacrolimus treatment before reperfusion correlated with 42% and 43% reductions in tissue polymorphonuclear leukocyte (myeloperoxidase) content (P <.008) and marked reductions in bronchoalveolar lavage leukocyte accumulation (P <.01). Administration of cyclosporine or tacrolimus at the time of reperfusion or 2 hours into the reperfusion period offered little or no protection. Animals treated before reperfusion also demonstrated marked reductions in nuclear factor kappaB activation and expression of proinflammatory cytokine messenger RNA.
Cyclosporine and tacrolimus treatment before reperfusion was protective against lung ischemia-reperfusion injury in rats. The mechanism of these protective effects may involve the inhibition of nuclear factor kappaB, a central transcription factor mediating inflammatory injury. The decreased expression of cytokine messenger RNA indicates that both cyclosporine and tacrolimus may exert their protective effects at the pretranscriptional level.
钙调神经磷酸酶抑制剂可减轻肝脏、脑、心脏、肾脏和小肠的实验性再灌注损伤。进行这些研究以确定这些药物对肺缺血 - 再灌注损伤是否同样具有保护作用。
雄性大鼠的左肺缺血90分钟,再灌注长达4小时。治疗组动物在缺血前6小时、再灌注时或再灌注后2小时接受环孢素A(国际非专利药品名称:环孢菌素;1或5mg/kg)或他克莫司(0.2mg/kg)。通过组织多形核白细胞积聚(髓过氧化物酶含量)、血管通透性(碘125标记的牛血清白蛋白外渗)和支气管肺泡灌洗白细胞含量来定量损伤。对单独的组织样本进行核蛋白和细胞因子信使核糖核酸处理。
再灌注前6小时用环孢素(5mg/kg)或他克莫司(0.2mg/kg)治疗,与对照动物相比,肺血管通透性分别降低了54%和56%(P<.03)。再灌注前环孢素和他克莫司治疗的保护作用与组织多形核白细胞(髓过氧化物酶)含量分别降低42%和43%相关(P<.008),并且支气管肺泡灌洗白细胞积聚明显减少(P<.01)。在再灌注时或再灌注2小时时给予环孢素或他克莫司几乎没有或没有保护作用。再灌注前治疗的动物还表现出核因子κB活化和促炎细胞因子信使核糖核酸表达明显降低。
再灌注前用环孢素和他克莫司治疗可保护大鼠免受肺缺血 - 再灌注损伤。这些保护作用的机制可能涉及抑制核因子κB,这是一种介导炎症损伤的关键转录因子。细胞因子信使核糖核酸表达的降低表明环孢素和他克莫司可能在转录前水平发挥其保护作用。